
“Prevention should be recognised as the first step in the AMR fight: every infection prevented is an opportunity to reduce antibiotic use or even overuse and to decrease the pressure driving resistance.”
By Dr. Christian Terreaux, Public Affairs Director at OM Pharma.
Industry’s role in AMR is usually discussed in terms of new antibiotics. What role should companies working on prevention play, and is that role recognised in AMR policy today?
Companies working on prevention should be seen as an integral part of the AMR solution. The traditional industry role has focused heavily on developing new antibiotics, which remains essential. But we also need to reduce the number of infections that require antibiotics in the first place.
Prevention companies can contribute through new vaccines and other evidence-based preventive interventions targeting either the pathogenic agent or the host immune system, and other approaches that reduce recurrent infections and therefore potentially reduce antibiotic use, misuse or overuse.
This role is increasingly recognised at the policy level. The 2024 UN Political Declaration on Antimicrobial Resistance represents an important shift because prevention is explicitly part of the AMR response. WHO highlights commitments to stronger infection prevention and control, vaccination, WASH and broader prevention strategies. But there is still a gap between political recognition and implementation. AMR policies, funding mechanisms and incentives still tend to give much greater visibility to antimicrobial R&D and stewardship than to innovations specifically designed to prevent infections. BEAM Alliance, the association of European Biotechs innovating in AMR, is now also focusing on prevention, beside diagnostics and prevention.
Preventing recurrent infections, such as respiratory and urinary tract infections, reduces the need for antibiotics. What evidence would convince health systems to invest in prevention at scale, and what is holding them back?
The key is to make the value of prevention measurable in AMR terms. For recurrent infections, health systems need evidence not only of fewer infections, but of fewer antibiotic prescriptions, fewer healthcare visits, better quality of life, and ultimately lower healthcare and societal costs.
What holds prevention back is probably that health systems are still more often structured to pay for treatment rather than reward an infection that never happened. And traditional health-economic models do not always capture the wider value of reducing antibiotic exposure and AMR.
So, if we want prevention to scale, we therefore need to make antibiotic use avoided a meaningful outcome alongside infections prevented and healthcare costs saved. We, at OM Pharma, have generated new evidence on those aspects, which clearly makes the case more convincing.
The updated Global Action Plan on AMR 2026 to 2036 puts prevention at the centre. How can industry, governments and health professionals work together to turn that into practice?
We need to turn prevention from an AMR aspiration into a measurable intervention. Governments should put infections prevented and antibiotic courses avoided into national AMR plans and ensure reimbursement and HTA systems recognise that value. Health professionals need to bring prevention into antimicrobial stewardship, particularly for patients experiencing recurrent respiratory or urinary infections.
And industry needs to provide robust evidence, not just on clinical efficacy, but on antibiotic use, recurrence, healthcare utilisation and economic value.
So there is a very clear action for different sectors: industry generates innovation and evidence, governments create the enabling framework, and healthcare professionals translate prevention into patient care.
That’s the reason why with BEAM Alliance, we are promoting the Policy Brief on “A PREVENTATIVE APPROACH TO RECURRENT INFECTIONS AND ANTIMICROBIAL RESISTANCE” beam-alliance-amr-policy-brief-october-2026.pdf
By Dr. Christian Terreaux
Public Affairs Director at OM Pharma.